Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Epsilon HealthcareASX:EPN EV-to-OCF is -6.22 as of Aug. 06, 2026. The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Epsilon Healthcare ranks better than 78.55% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Epsilon Healthcare's Enterprise Value is A$19.45 Mil.
Epsilon Healthcare's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.13 Mil. Therefore, Epsilon Healthcare's EV-to-OCF for today is -6.22.
The historical rank and industry rank for Epsilon Healthcare's EV-to-OCF or its related term are showing as below:
ASX:EPN'
s EV-to-OCF Range Over the Past 10 Years
Min: -38.42 Med: -4.29 Max: -1.04
Current: -6.22
During the past 9 years, the highest EV-to-OCF of Epsilon Healthcare was -1.04. The lowest was -38.42. And the median was -4.29.
ASX:EPN's EV-to-OCF is ranked better than 78.55% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.73
vs ASX:EPN: -6.22
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Epsilon Healthcare's PE Ratio (TTM) for today is calculated as:
Epsilon Healthcare's share price for today is A$0.024.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Epsilon Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Epsilon Healthcare EV-to-OCF Related Terms
Epsilon Healthcare EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Epsilon Healthcare's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Epsilon Healthcare's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epsilon Healthcare EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Epsilon Healthcare's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Epsilon Healthcare's EV-to-OCF falls into.
Epsilon Healthcare's current Enterprise Value is A$19.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Epsilon Healthcare's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epsilon Healthcare (ASX:EPN) has a EV-to-OCF of -6.22 as of Aug. 06, 2026. According to the industry distribution chart, Epsilon Healthcare ranks #216 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 21.4%.
Is Epsilon Healthcare's EV-to-OCF too high?
Epsilon Healthcare's current EV-to-OCF is -6.22. Based on the distribution chart, Epsilon Healthcare ranks #216 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Epsilon Healthcare's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Epsilon Healthcare ranks #216 out of 1007 companies for EV-to-OCF. This places Epsilon Healthcare in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 10.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.73, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epsilon Healthcare's current EV-to-OCF is -6.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epsilon Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Epsilon Healthcare (ASX:EPN) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.02 — trading 20% below its estimated fair value. The current EV-to-OCF is -6.22. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Epsilon Healthcare (ASX:EPN), the current EV-to-OCF is -6.22 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Epsilon Healthcare Ltd is an Australian based, globally active healthcare organisation. It operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacturing operation & pharmacy services. The company offers end-to-end solutions across the healthcare spectrum: from product development and manufacturing to patient care. The company's three (3) main operating segments are: a. Contract Development and Manufacturing activities, b. Telehealth medical practice services; and c. Pharmacy services. The majority of revenue is derived from the Contract Development and Manufacturing activities segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EPN has been successfully added to your 
